New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 18, 2014
08:33 EDTVRTX, JNJVertex licenses VX-787 to Janssen for treatment of influenza
Vertex Pharmaceuticals (VRTX) announced that it has entered into a licensing agreement with Janssen Pharmaceuticals (JNJ) for the worldwide development and commercialization of VX-787, a novel medicine discovered by Vertex for the treatment of influenza. As part of the agreement, Vertex will receive an up-front payment of $30M from Janssen and has the potential to receive additional development and commercial milestone payments as well as royalties on future product sales. Vertex completed a Phase 2a study of VX-787 in 2013 that showed statistically significant improvements in viral and clinical measurements of influenza infection. VX-787 is designed to directly inhibit replication of the influenza virus. Under the terms of the collaboration, Janssen will have full global development and commercialization rights to VX-787. Vertex will receive a $30M up-front payment from Janssen and could receive additional development and commercial milestone payments as well as royalties on future product sales. The collaboration, and the related $30M up-front payment, is subject to the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act.
News For VRTX;JNJ From The Last 14 Days
Check below for free stories on VRTX;JNJ the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 31, 2014
16:42 EDTVRTXVertex receives European approval for KALYDECO in eight gating mutations
Vertex Pharmaceuticals announced that the European Commission has approved KALYDECO for people with cystic fibrosis ages 6 and older who have one of eight non-G551D gating mutations in the cystic fibrosis transmembrane conductance regulator gene. KALYDECO was first approved in Europe in July 2012 for people with CF ages 6 and older who have the G551D mutation, which is the most common gating mutation. The eight additional gating mutations included in today’s approval are G178R, S549N, S549R, G551S, G1244E, S1251N, S1255P and G1349D. In Europe, approximately 250 people ages 6 and older have one of these non-G551D gating mutations.
16:17 EDTJNJPharmacyclics says $60M Janssen milestone payment to be recognized in Q3
Subscribe for More Information
10:35 EDTJNJJohnson & Johnson should get new Zytiga patent shortly, says Wells Fargo
Subscribe for More Information
07:23 EDTJNJJ&J withdrawing laparoscopic power morcellators from market, AP says
Subscribe for More Information
July 30, 2014
07:50 EDTJNJSenate Judiciary Committee to hold a hearing
Subscribe for More Information
July 29, 2014
16:23 EDTVRTXVertex reports Q2 EPS (68c), consensus (72c)
Reports Q2 revenue $138M, consensus $132.06M.
15:53 EDTVRTXNotable companies reporting after market close
Subscribe for More Information
08:50 EDTJNJHarris & Harris invests in Accelerator Corporation
Subscribe for More Information
July 28, 2014
13:20 EDTJNJPharmacyclics granted regular approval for Imbruvica
Subscribe for More Information
12:26 EDTJNJPharmacyclics off lows, turns positive after FDA expands Imbruvica indication
Subscribe for More Information
12:24 EDTJNJFDA expands approved use of Imbruvica for chronic lymphocytic leukemia
The U.S. Food and Drug Administration today expanded the approved use of Imbruvica to treat patients with chronic lymphocytic leukemia who carry a deletion in chromosome 17, which is associated with poor responses to standard treatment for CLL. Imbruvica received a breakthrough therapy designation for this use. The FDA is also approving new labeling to reflect that Imbruvica’s clinical benefit in treating CLL has been verified. Imbruvica’s new use is being approved more than two months ahead of the product’s prescription drug user fee goal date of Oct. 7, the date the FDA was scheduled to complete review of the drug application. Imbruvica also received accelerated approval in November 2013 for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy. Clinical studies to verify and describe Imbruvica’s clinical benefit in mantle cell lymphoma are ongoing. Imbruvica is being jointly developed and commercialized in the United States by Pharmacyclics (PCYC) and Janssen Biotech (JNJ).
06:32 EDTJNJJ&J dispute with Boston Scientific looks set to go to trial, NY Times says
Subscribe for More Information
July 25, 2014
08:54 EDTJNJEMA issues positive opinion, recommends approval of Imbruvica
Subscribe for More Information
07:17 EDTJNJEMA recommends approval for Gilead, Janssen blood cancer drugs
Subscribe for More Information
July 24, 2014
09:16 EDTJNJOn The Fly: Pre-market Movers
Subscribe for More Information
08:39 EDTJNJOrganovo enters 3D bio-printed tissue agreement with J&J unit
Organovo (ONVO) announced that it has entered into an agreement with Janssen Research and Development, a pharmaceutical company of Johnson & Johnson (JNJ), to evaluate the use of 3D bio-printed tissue in a drug discovery setting, outside of the company’s work in 3D liver tissue for toxicity testing. Terms were not disclosed.
08:19 EDTJNJLeerink medical devices analyst holds an analyst/industry conference call
Subscribe for More Information
July 21, 2014
18:40 EDTJNJOn The Fly: After Hours Movers
UP AFTER EARNINGS: Netflix (NFLX), up marginally after reporting Q2 results... Sanmina (SANM), up 13.2% after reporting third quarter results and fourth quarter guidance above analyst estimates... Chipotle (CMG), up 10.1%... Helix (HLX), up 5.2%... Canadian National (CNI), up 1.13%... CYS Investments (CYS), up 1.7%. ALSO HIGHER: Apache (APA), up 5% after Bloomberg says JANA discloses $1B position... Johnson & Johnson (JNJ), up 1% after announcing a $5B share repurchase program... TG Therapeutics (TGTX), up 4.3% after reporting second quarter results and preliminary clinical results from TG-1101 Phase I study... DOWN AFTER EARNINGS: Rambus (RMBS), down 3.6% after reporting second quarter results... Ultra Clean (UCTT), down 4% after reporting quarterly results. ALSO LOWER: Tallgrass Energy (TEP), down 5% after filing to sell 7M common units representing limited partners.
17:03 EDTJNJJohnson & Johnson announces $5B share repurchase program
Johnson & Johnson announced that its board has approved the repurchase of up to $5B of the company's common stock. The company had approximately 2.82B shares of common stock outstanding as of June 29.
17:01 EDTJNJJohnson & Johnson announces $5B share repurchase program

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use